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ABSTRACT: The use of alternative specimens in the field of toxicology was first described in 1979, when hair analysis was used
to document chronic drug exposure. Since then, the use of these ‘alternative’ samples has gained tremendous importance in foren-
sic toxicology, as well as in clinic toxicology, doping control and workplace drug testing. It is not surprising, therefore, that a large
number of papers dealing with the determination of several classes of drugs in saliva, sweat, meconium and hair have been
published ever since, owing to the fact that chromatographic equipment is becoming more and more sensitive, mass spectrometry
(and tandem mass spectrometry) being the most widely used analytical tool, combined with gas or liquid chromatography. ‘Alter-
native’ specimens present a number of advantages over the ‘traditional’ samples normally used in toxicology (e.g. blood, urine and
tissues), namely the fact that their collection is not invasive, their adulteration is difficult, and they may allow increased windows
of detection for certain drugs. The main disadvantage of this kind of samples is that drugs are present in very low concentrations,
and therefore high-sensitivity techniques are required to accomplish the analysis. This paper reviews a series of publications on
the use of alternative specimens, with special focus on the main analytical and chromatographic problems that these samples
present, as well on their advantages and disadvantages over traditional samples in documenting drug exposure. Copyright © 2008
John Wiley & Sons, Ltd.
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In the last decade, alternative or unconventional matri-
ces have becoming more important in the field of
toxicology, owing to the advantages that these speci-
mens present when compared with ‘conventional’
samples used in laboratorial routine analysis. In general
these samples present the advantage that collection
is almost non-invasive and easy to perform. On the
other hand, collection can also be achieved under close
supervision, which prevents sample adulteration or sub-
stitution. Furthermore, some of these samples present
larger detection windows, and therefore their range of
analytical applications can be very wide.
Recent advances in analytical techniques have en-
abled the detection of drugs and metabolites at very low
concentrations that were unthinkable a few years ago.
In fact, LC/MS and LC/MS/MS techniques are increas-
ing in popularity as confirmation techniques because of
high sensitivity and specificity, and the ability to handle
complex matrices. Also, LC/MS techniques do not
require the time-consuming derivatization steps needed
in GC/MS for a large number of compounds; how-
ever, ion suppression or enhancement due to complex
matrices is a frequent analytical complication and
must be addressed during method development and
validation.
In fact, despite the analytical problems that liquid
chromatography-based techniques can present, these
are the state of art concerning analysis of alternative
specimens because of their higher sensitivity, which is
crucial if one takes into account the low amount of
sample usually available in these situations.
Therefore, very low amounts of drugs of abuse or pre-
scription drugs can be detected, for instance in the low
picogram range for carboxy-THC, which is definite proof
of cannabis consumption, using hair analysis, and for
benzodiazepines, a single exposure to which in a drug-
facilitated assault can be detected through hair analysis.
The first unconventional sample used was hair in the
1960s and 1970s to evaluate human exposure to toxic
heavy metals, namely arsenic, lead and mercury (Ham-
mer et al., 1971; Kopito et al., 1967). Since then, numer-
ous papers dealing with the determination of various
classes of compounds have been published in the scien-
tific literature, normally concerning drugs of abuse and
therapy. Nowadays other alternative samples such as
oral fluid, meconium or sweat are being introduced and
present a wide range of applications, e.g. in therapeutic
drug monitoring, workplace drug testing and prenatal
exposure to drugs of abuse.
This review will deal with the most used unconven-
tional samples, with special focus on their advantages
and disadvantages, collection procedures, classes of
drugs that are analyzed and analytical methods.
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ALTERNATIVE SPECIMENS
The most commonly used unconventional samples are
hair, oral fluid, sweat and meconium. The physiological
and analytical properties of these samples, as well of
other (less used) samples, including advantages and
drawbacks of each and the main parameters that can
affect their analysis, will be discussed below, in the light
of existing literature on the topic.
Hair
Hair is a product of differentiated organs in the skin of
mammals. It is constituted by proteins, mainly keratin
(65–95%), water (15–35%), lipids (1–9%) and miner-
als (0.25–0.95%; Harkley and Henderson, 1989). A rich
capillary system, which provides the growing hair with
the necessary metabolic material, surrounds the hair
follicle (Pragst and Balikova, 2006). It is estimated that
the total number of hair follicles in adults is approxi-
mately 5 million. Hair grows at a rate of 0.6–1.4 cm per
month, depending on the type of hair and anatomical
site (Saitoh et al., 1969).
The hair growth cycle is divided into the anagen (active
growing), catagen (transition) and telogen (resting) stages.
The proportions of anagen/telogen hair vary with ana-
tomical site and this feature, together with variable
growth rate, accounts for the observed differences
in drug concentrations in hair collected from different
regions. In fact, not only scalp hair can be used for
analysis, and pubic hair, arm or leg hair and axillary
hair have been suggested as alternative sources for drug
detection when scalp hair is not available. However,
care should be taken when interpreting the concentra-
tions of drugs in these specimens, since various studies
have found differences between pubic or axillary hair
and scalp hair (Balabanova and Wolf, 1989; Offidani
et al., 1993; Han et al., 2005). Indeed, the latter two
studies have compared methadone and methamphe-
tamine concentrations in hair from different anatomical
sites, concluding that the highest values were found
in axillary hair, followed by pubic hair and scalp hair.
In contrast, in another study the highest morphine con-
centrations were found in pubic hair, followed by head
hair and axillary hair (Mangin and Kintz, 1993). The
significant differences of the drug concentrations in
these studies can be explained not only by the totally
different anagen/telogen ratio or growth rate, but also
by a better blood circulation and a greater number of
apocrine glands (Pragst et al., 1998).
Beard hair is also a suitable specimen for analysis.
This type of hair grows at about 0.27 mm per day, and
therefore can be collected on a daily basis with an elec-
tric shaver.
Hair analysis is only useful if the measured drugs are
a result of ingestion, rather than from other sources.
Therefore, the mechanisms of incorporation of the
drugs into the hair shaft must be addressed. It is gener-
ally accepted that drugs can enter the hair from three
sources: (1) from the bloodstream during hair growth;
(2) following excretion by sweat and sebum bathing the
hair, usually after the hair emerges from the skin, and
(3) from passive exposure from the hair to the drug,
e.g. from smoke or dirty hands, followed by dissolution
of the drug into the drug-free sweat. It is virtually
impossible to distinguish between the presence of drugs
derived from these two latter mechanisms and that pro-
ceeding from actual consumption, which is explained
by the fact that the drugs are in an aqueous moiety,
enhancing their incorporation. This is the reason why
environmental exposure is sometimes called the ‘stum-
bling block of hair testing’ (Kidwell and Blank, 1996).
Incorporation of drugs is affected by the melanin
content of the hair and by the substances’ lipophilicity
and basicity. For instance, the effect of melanin content
of the hair on drug incorporation can be studied in
individuals with gray hair, showing that the concentra-
tion of basic drugs in pigmented hair can be about
10-fold higher than in non-pigmented hair (Pragst and
Balikova, 2006). In fact, it has been suggested that
drugs bind to melanin, which explains the higher con-
centrations normally found in darker hair (Rollins
et al., 2003; Mieczkowski and Kruger, 2007).
Hair samples are best collected from the back of the
head, the so-called vertex posterior. In fact, this is the
region where hair grows with more homogeny, and
also where the anagen/telogen ratio is higher, meaning
that the number of hairs in active growth is larger. Hair
should be cut as close as possible to the scalp with the
aid of scissors, and the proximal zone (i.e. the zone
which is closer to the root) should be clearly indicated
if segmental analysis is to be performed. The sample
can then be stored light and moisture protected at room
temperature, for instance wrapped in aluminum foil.
Drugs are usually stable in regularly treated hair
(without using aggressive cosmetic agents, such as oxi-
dant dyes, bleaching or permanent wave), which makes
them detectable for at least one year after intake
(Pragst and Balikova, 2006).
Hair is usually exposed to several agents that may
impair drug testing, such as shampoos, dust, sunlight
and rain. In fact, there are several studies on the effect
of cosmetic treatments on drug stability in hair. For
example, Martins et al. (2007) have found that the con-
centrations of amphetamine-type stimulants decreased
in bleached hair when compared with non-bleached
hair, without influencing their enantiomeric ratios.
Likewise, it has been shown that this treatment affects
the stability and decreases hair concentrations of other
drugs (Pötsch and Skoop, 1996; Yegles et al., 2000).
Cosmetic treatments can also produce analytical inter-
ferences that may hinder the detection of drugs. This is
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the case for minoxidil, whose TMS derivative prevents
the detection of cocaine and metabolites (Zucchela
et al., 2007).
As stated above, one of the most important pitfalls
in hair analysis is environmental contamination. Indeed,
if adequate measures are not taken, the risk of report-
ing false positive results increases, which is unaccept-
able, especially if there are legal implications of drug
consumption. Therefore, to minimize this effect it is
strongly recommended that hair analysis procedures
include a washing step. Several decontamination proce-
dures are described in the literature, and these include
organic solvents, aqueous buffers, water, soaps and
combinations of these (Kintz et al., 1995; Eser et al.,
1997; Girod and Staub, 2000; Skender et al., 2002;
Schaffer et al., 2002; Villamor et al., 2005). There is
no general consensus regarding decontamination pro-
cedures, and it is assumed that the total elimination
of deposited drug is not achieved even after laborious
washing procedures. Several researchers propose crite-
ria for differentiation between drug use and environ-
mental contamination, namely the establishment of a
concentration ratio between the last wash and the hair
sample (Schaffer et al., 2005; Tsanaclis and Wicks,
2007a).
Hair decontamination prior to analysis is not the
only way to deal with environmental exposure. There-
fore, the Society of Hair Testing also recommends the
detection of drug metabolites and the use of metabolite
to parent drug ratios to report positive results (Society
of Hair Testing, 2004). In fact, as environmental con-
tamination is not totally removed even using laborious
washing techniques, only the detection of drug metabo-
lites, i.e. proceeding from endogenous metabolism,
guarantees that the drug that is being measured has
been actively consumed. This is of particular impor-
tance in the case of drugs that are likely to be in the
environment because of the way they are consumed,
such as cannabis (THC-COOH should be detected)
and cocaine (where at least one metabolite should be
detected, with a concentration ratio to the parent drug
of higher than 0.05).
The major practical advantage of hair testing com-
pared with urine or blood testing for drugs is that it
has a larger detection window (weeks to months,
depending on the length of the hair shaft, against 2–4
days for most drugs). However, it is not advisable to
rely only on hair analysis, since there are issues where
it cannot provide adequate results, such as short-term
information on an individual’s drug use, for which blood
and/or urine are better specimens. On the other hand,
long-term histories are only accessible through hair
analysis. Therefore, one can say that these tests com-
plement each other.
The assessment of this ‘chronic exposure’ to drugs is
achieved by segmental hair analysis. In fact, hair grows
at approximately 1 cm per month, and it is possible to
associate the drug distribution pattern in the analyzed
segments with a period in the past, taking into account
both variable hair growth rates and intra- and inter-
individual differences. Furthermore, drugs are very stable
within the hair matrix for long periods of time, provid-
ing that specimens are stored light- and moisture-
protected. Another advantage of hair analysis when
compared with blood or urine analysis is the collection
procedure, because: (1) it is non-invasive and easy to
perform; (2) the sample is not easy to adulterate by
diluting with water (as can occur in urinalysis); and (3)
in the case that there is a claim (sample switching,
break in the chain of custody, etc.), it is possible to
get an identical sample from the subject. Obviously,
this latter is of great importance in the field of forensic
toxicology.
However, hair analysis has several drawbacks, which
sometimes are very difficult to handle in manageable
proportions. The main problem in this type of analysis
is the possibility of reporting false positive results
due to environmental contamination of the hair, which
can occur at any level. The fact that a drug is detected
in a hair specimen does not necessarily mean that
it was actively consumed. Therefore, hair specimens
should be decontaminated prior to analysis, and specific
metabolites of the drugs must be searched for. This
may present a problem, because normally the metabo-
lites are more polar drugs, and have less affinity for
hair matrix constituents. This is the case, for example,
for THC-COOH, the metabolite of THC (cannabis
main constituent), which is found in hair in extremely
low concentrations, usually in the low picogram range.
To detect these low concentrations, mass spectrometric
techniques are mandatory, using either gas or liquid
chromatography.
In addition, as hair is quite a ‘dirty’ matrix, its con-
stituents may interfere with chromatographic analysis,
and therefore a sample cleanup step is normally re-
quired. In the development of new methods for drug
detection in hair, special attention should be paid to the
matrix effect, especially using liquid chromatographic
methods, because they are more sensitive to ion sup-
pression/enhancement effects.
Since the first report in the 1970s, hair analysis has
aided toxicologists in several fields, such as in history
and archaeology (Nakahara et al., 1997; Báez et al., 2000),
in assessing consumption profiles of drugs and alcohol
by the general (Jurado et al., 1996; Hartwig et al., 2003;
Tsanaclis and Wicks, 2007b) or student populations
(Kidwell et al., 1997; Quintela et al., 2000), driving
licence renewals (Ricossa et al., 2000), assessing intra-
uterine drug exposure (Chiarotti et al., 1996; Ursitti et al.,
1997; Koren et al., 2002; Garcia-Bournissen et al., 2007),
evaluating of compliance with drug substitution therapy
(Moeller et al., 1993; Kintz et al., 1998; Lucas et al.,
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2000; Sabzevari et al., 2004), in the workplace and pre-
employment (Cairns et al., 2004) and in post-mortem
toxicology (Kintz, 2004). Another important application
of hair analysis is in drug-facilitated crimes, in which
the analytes must be detected after a single exposure,
which is achieved due to the high sensitivity of LC/MS/
MS (Negrusz and Gaensslen, 2003; Kintz, 2007).
Several classes of drugs can be detected in hair, such
as biomarkers of alcohol consumption, cocaine and meta-
bolites, opiates, cannabinoids, amphetamines and other
designer drugs, GHB, benzodiazepines and hypnotics,
antipsychotics, antidepressants, steroids, anaesthetics,
antiparkinsonics and alkaloids (Table 1).
Hair analysis usually begins with a general screening
by immunoassays, followed by a confirmation using
chromatographic techniques. Gas chromatography
coupled to mass spectrometry is by far the most widely
used analytical tool for drug determination in hair
specimens. Nevertheless, liquid chromatography–mass
spectrometry (or tandem mass spectrometry) based
methods are becoming more and more important in
this field, owing to their better sensitivity for termo-
labile compounds, yielding lower limits of detection
and quantitation, and the fact that time-consuming
derivatization steps are not necessary to accomplish the
analysis. However, before chromatographic analysis,
the analytes must be (1) extracted from within the
matrix (where they are bound to hair constituents)
and (2) concentrated in a solvent which is compatible
with the analytical instruments. There is no universal
method to extract the analytes from the hair matrix,
and it depends on the nature and chemical stability
of the particular compound. Therefore, opioids and
cocaine are best extracted using mild acidic hydrolysis
(e.g. 0.05–0.5 M hydrochloric acid), to avoid conversion
of heroin or 6-acetylmorphine to morphine and of
cocaine to benzoylecgonine (Girod and Staub, 2000;
Romano et al., 2003; Cognard et al., 2005; Cordero
et al., 2007; Tsanaclis and Wicks, 2007a). On the other
hand, stable compounds like cannabinoids and amphe-
tamines can be extracted using strong alkaline con-
ditions (e.g. 1 M sodium hydroxide; Quintela et al., 2000;
Stanaszek and Piekoszewski, 2004; Villamor et al., 2005;
Martins et al., 2005, 2006; Tsanaclis and Wicks, 2007a).
Other extraction methods include buffer or solvent
extraction (with, or without sonication; Paterson et al.,
2001; Scheidweiler and Huestis, 2004) and enzymatic
hydrolysis (Vincent et al. 1999; Quintela et al., 2000;
Míguez-Framil et al., 2007).
Following this extraction step, which is normally the
most time-consuming step in hair analysis, a sample
cleanup step is often required, to minimize any interfer-
ence caused by endogenous compounds, which is particu-
larly important in the case of liquid chromatography-
based methods because of ion suppression/enhancement
effects. This sample cleanup procedure is usually per-
formed using liquid–liquid extraction (Sachs and Dressler,
2000; Stanaszek and Piekoszewski, 2004; Villamor et al.,
2005; Nakamura et al., 2007) or solid-phase extraction
(Girod and Staub, 2000; Scheidweiler and Huestis,
2004; Cognard et al., 2005; Martins et al., 2006; Moore
et al., 2006a,b; Lachenmeier et al., 2006; Cordero and
Paterson, 2007). However, solid-phase microextrac-
tion (Sporkert and Pragst, 2000; Lucas et al., 2000;
Musshoff et al., 2002; Nadulski and Pragst, 2007), solid-
phase dynamic extraction (Musshoff et al., 2003) and
supercritical fluid extraction (Cirimele et al., 1995;
Allen and Oliver, 2000; Brewer et al., 2001) have also
been described.
Saliva/oral fluid
Saliva is the excretion product originated from three
pairs of major salivary glands (parotid, submandibular
and sublingual), a great number of minor salivary glands,
the oral mucosa and gingival crevices. As this excretion
product is actually a fluid mixture, the term ‘oral fluid’
seems more appropriate to designate it, instead of ‘saliva’
or ‘whole saliva’ (Malamud, 1993). Water (99%) is the
major oral fluid constituent, and other components
such as proteins (mucins and digestion enzymes) and
mineral salts are also present. Its pH is 6.8 in resting
situations, but an increase in the salivary flow turns
it more basic (approaching the plasma’s pH) as a result
of higher osmolarity (Kintz and Samyn, 2000). All these
characteristics are influenced by a variety of factors,
as the circadian rhythm, the type of the salivation stimu-
lus, hormonal changes, stress, and therapeutic drugs
(Aps and Martens, 2005). The total volume of oral fluid
produced by an adult may be 1000 mL/day with typical
flows of 0.05 mL/min while sleeping, 0.5 mL/min while
spitting and 1–3 mL/min or more while chewing (Crouch,
2005).
Different mechanisms of drug transport are thought
to occur, such as passive diffusion through the membrane,
active processes against a concentration gradient, filtra-
tion through pores in the membrane and pinocytosis
(Spihler, 2004). Most of the drugs enter oral fluid by a
mechanism of passive diffusion, which is dependent on
the particular physicochemical properties of the com-
pound or class of compounds, such as molecular weight
(a molecular weight of less than 500 Da favors dif-
fusion), liposolubility, pH and pKa, protein binding and
ionization state (Paxton, 1979; Aps and Martens, 2005).
Therefore, the concentrations of drugs in oral fluid
represent the free non-ionized fraction in the blood
plasma. In fact, the fraction of drug bound to saliva and
plasma protein as a function of pKa and pH can be pre-
dicted by the Henderson–Hasselbach equation (Spihler,
2004).
A variety of methods are available for oral fluid
collection (Navazesh, 1993), including spitting, draining,
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suction and collection on various types of absorbent
swabs.
Several techniques may be used to collect stimulated
saliva. The simplest involves tongue, cheek or lip move-
ments without any external stimulus (Mucklow et al.,
1978). Chewing paraffin wax, Parafilm, teflon, rubber
bands, gum base and chewing gum are usually referred
to as mechanical methods of stimulating saliva pro-
duction. Likewise, a lemon juice drop or citric acid can
be placed in the mouth to provide a gustatory stimulus
for saliva production (Crouch et al., 2004). However, the
stimulation of saliva production may present several
problems which can compromise drug-testing accuracy.
For instance, some drugs and/or metabolites have been
shown to be absorbed by Parafilm, and citric acid
stimulation changes saliva pH and may alter drug con-
centrations. On the other hand, citric acid and cotton
have also been shown to alter immunoassay drug test
results (Crouch, 2005).
A variety of commercial collection devices that pro-
mote easy, quick and reproducible collection are available.
In general, these devices consist of a sorbent material
that becomes saturated in the mouth of the donor, and
after removal the oral fluid is recovered by applying
pressure or by centrifugation. Examples of commer-
cially available devices include Orasure® (Epitope, Inc.,
Beaverton, OR, USA), Omni-SAL® (Cozart Biosciences Ltd,
Abington, UK), Salivette® (Sarstedt AG, Rommelsdorf,
Germany), Drugwipe® (Securetec, Ottobrunn, Germany),
Intercept® ORALscreen™ and Quantisal™ (Immunalysis
Corp., Pomona, USA; Spihler, 2004; Samyn et al., 2007).
Care should be taken when using these collection
devices, because deficient recovery of drugs from oral fluid
in the absorbent and adsorption of the drug on device
components are likely to occur (Lenander-Lumikari
et al., 1995; O’Neal et al., 2000; Samyn et al., 2007).
One of the advantages of saliva testing is that the sample
is collected under direct supervision without loss of pri-
vacy. In consequence, the risk of an invalid specimen
being provided or sample adulteration and/or substitu-
tion (which are likely to occur in urine analysis) is reduced.
In addition, monitoring of oral fluid may be especially
advantageous and important when multiple serial samples
are needed or when drug concentrations in children are
required (Kim et al., 2002). Other advantages are that,
in principle, saliva drug concentrations can be related
to plasma free-drug concentrations and to the pharma-
cological effects of drugs.
On the other hand, drugs that are ingested orally as
well as those that can be smoked may be detected
in high concentrations in oral fluid following recent use,
due to residual amounts of drug remaining in the oral
cavity. Therefore, and for these substances, results
may not be accurate because the drug concentration
found in the oral fluid may not reflect the blood-drug
concentration.
Another disadvantage of studying oral fluid is that
people are sometimes unable to produce sufficient
amounts of material for analysis. Moreover, an impor-
tant feature of urine testing is the accuracy of the
on-site tests to detect drugs of abuse in fresh samples.
Unfortunately, this is not the current situation for
oral fluid testing (Grönholm and Lillsunde, 2001; Kintz
et al., 2005a). In addition, oral fluid contains several
macromolecules (mucopolysaccharides and mucoproteins),
which make it less easily pipetted than for instance
urine, and may not be available from all individuals
at all times, since there are drugs that can inhibit
saliva secretion and cause dry mouth. Furthermore,
and because drug concentration on this sample depends
on plasma drug concentrations, drugs that have a short
plasma half-life and are cleared rapidly from the body
are detectable in saliva for a short time only, which
represents a potential disadvantage over hair, sweat or
urine. In fact, saliva and blood have the shortest detec-
tion windows (Spihler, 2004).
Because of the above-mentioned advantages, oral
fluid testing is an analytical tool used in therapeutic
drug monitoring of various drugs (Horning et al. 1977;
Bennett et al., 2003; Quintela et al. 2005; Dams et al.,
2007), pharmacokinetic studies (Schepers et al., 2003;
Huestis and Cone, 2004; Huestis, 2005; Drummer, 2005;
Kauert et al., 2007), and detection of illicit drugs in
impaired driving (Samyn et al., 2002b; Kintz et al.,
2005a; Toennes et al., 2005; Wylie et al., 2005a,b;
Laloup et al., 2006; Concheiro et al., 2007; Drummer
et al., 2007; Pehrsson et al., 2007).
There is no doubt that one of the most impacting
applications of oral fluid testing is in the assessment
of drug-impaired driving, enabled not only by the
development of several on-site collection devices, but
also its easy and non-invasive sample collection pro-
cedure. In addition, the premise of a good correlation
between oral fluid levels and blood levels means that
oral fluid levels may be used to assess the degree of
impairment of a driver.
Drugs of abuse are by far the most frequently
detected substances in oral fluid specimens, because
of their implications in workplace medicine and motor
vehicle driving. Therefore, methods are described to
detect opiates, cannabinoids, amphetamines, cocaine,
benzodiazepines and other substances such as ketamine,
GHB, antibiotics, analgesics, cyanides and other tobacco
compounds, and sildenafil (Table 2).
One issue that is gaining popularity within law en-
forcement and traffic regulation agencies is that the
initial testing of oral fluid for drugs can be made in the
field, by means of on-site collecting devices. Several
devices are commercially available for this purpose,
including instruments that provide an electronic readout
(e.g. Dräger DrugTest® and Orasure Uplink®, Cozart
Rapiscan® and Drugread® hand photometer) and
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hand-held cartridges that require visual identification,
i.e. providing a visual readout (e.g. DrugWipe®, iScreen
OFD™, OralScreen®, Oratect®, SalivaScreen™). The
main advantage of these devices is that they provide
a preliminary drug result within minutes without the
need for sophisticated laboratory screening equipment.
However, at the moment there is no objective way
to assess its performance, because there is a lack of
consistency in their specifications. For example, for
some of them, cut-off concentrations are used to define
their detectability, whereas for others concentrations
are given when drugs can be detected (Drummer,
2006). The apparent sensitivity is often not defined
in terms of consistency of detection in oral fluid
specimens.
Taking these facts into account, the results provided
by these devices must be confirmed in the laboratory.
Laboratorial techniques include screening procedures
by ELISA-based immunoassays, which in general are
adequate for opioids (Barnes et al., 2003; Kacinko et al.,
2004; Lachenmeier et al., 2006), methadone (Cooper
et al., 2005b), cocaine (Kolbrich et al., 2003; Kim
et al., 2003; Cooper et al., 2004; Lachenmeier et al.,
2006), amphetamines (Kupiec et al., 2002; Laloup et al.,
2005c; Cooper et al., 2006), and buprenorphine (De
Giovanni et al., 2005) and provide a reliable means to
screen oral fluid. Cannabis can be more difficult, par-
ticularly if the immunoassay has little cross-reactivity
to THC. Nevertheless enzyme immunoassay has been
successfully used for this drug (Niedbala et al., 2001;
Moore et al. 2006c). The same applies for benzodia-
zepines despite their low concentrations in oral fluid
(Kemp et al., 2002; Smink et al., 2006).
Concerning sample preparation techniques, analytes
can be extracted by liquid–liquid extraction (Campora
et al., 2006; Quintela et al., 2007; Pujadas et al., 2007),
solid-phase extraction with different types of extraction
cartridges (Mortier et al., 2002; Jones et al., 2002; Wood
et al., 2005; Ngwa et al., 2007), or even solid-phase
microextraction (Pragst, 2007).
The introduction of LC-MS as a routine laboratory
technique has enabled the benefits of high-performance
liquid chromatography (HPLC) separation techniques
to be linked to the high sensitivity and specificity of MS
(Drummer, 2006), which has assisted in the development
of drug testing in oral fluid due to the relatively small
sample volumes that can be obtained. In fact, concern-
ing oral fluid analysis, sample volume may present a
serious problem if several analyses are to be performed.
Mass-spectrometry-based methods have been also
used to screen for a range of drugs (Allen et al., 2005),
some allowing the quantitation of several drugs
(Gunnar et al., 2005; Campora et al., 2006; Scheidweiler
and Huestis, 2006; Peters et al., 2007; Concheiro et al.,
2007; Cone et al., 2007). By the use of GC-MS or LC-
MS including tandem mass spectrometry (MS-MS), low
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analytical limits can be achieved, even using sample
volumes as low as 0.1 mL.
The main analytical problem in oral fluid testing is
due to the nature of the sampling devices. Indeed,
these systems contain several stabilizers and preserva-
tives that are able to impair precise and accurate analy-
ses. This issue is of particular importance when LC-MS/
MS is used, as ion suppression or enhancement effects
are usually observed. Therefore, care must be taken
when developing new analytical procedures and the
possibility that these effects affect the precision and
accuracy of the assay must be documented. Several
papers addressing this issue have been published (Dams
et al., 2003; Annesley, 2003).
Another point of concern in oral fluid testing is drug
recovery from the collection device, which may have an
undesirable effect on the accuracy of the assay. In fact,
if the analytes are not fully recovered from the device,
the drugs’ concentration on the sample may be under-
estimated, with consequences for their oral fluid to
plasma ratio.
There have been published some recovery studies
using several collection devices, suggesting that desorp-
tion of drugs may limit the usefulness of some materi-
als. For instance, Salivette® has poor recovery for THC
but is reasonable for codeine, whereas the Cozart® col-
lector has good recovery for THC (Drummer, 2006).
For these reasons, more information on drug recovery
and stability is required, particularly for those drugs that
are likely to be measured in oral fluid.
Sweat
Sweat is a clear, hypotonic solution produced by two
types of glands: eccrine and apocrine located in epider-
mis (Sato et al., 1989). Water (99%) is its main con-
stituent, as well as high concentrations of sodium and
chloride. Low levels of potassium, glucose, lactic and
piruvic acids and urea are also present. The sweat from
apocrine glands also contains proteins and fatty acids.
Sweat acts physiologically by regulating body tempera-
ture, since its evaporation from the skin surface reduces
the excess heat. Sweating is increased by nervousness,
exercise, stress and nausea and decreased by cold. Sweat
excretion is also affected by other factors, such as ambi-
ent temperature, relative humidity, body location (in
general, sweat glands are distributed over the entire
body, except for the lips, nipples and external genital
organs), hormonal imbalances, overactive thyroid gland
and the sympathetic nervous system, and certain foods
and medications.
Between 300 and 700 mL/day of sweat is produced
over the whole body, whereas 2–4 L/h may be produced
by extensive exercise (Kintz and Samyn, 2000). Several
mechanisms of incorporation of drugs into sweat have
been suggested, including passive diffusion from blood
into sweat glands and transdermal passage of drugs across
the skin. Non-ionized basic drugs diffuse into sweat and
become ionized as a result of its lower pH (5.8) as com-
pared with blood (7.4) (Huestis et al., 1999). Generally,
parent drugs are found in sweat, rather than their
polar metabolites, which usually predominate in urine
(Follador et al., 2004). As sweat glands are associated
with hair, it is thought to be a major contributor to
drug appearance in hair, as stated above.
The analysis of drugs in sweat is rarely performed
because it is extremely difficult to estimate sweat
volume and evaluate drug concentrations, and also to
collect adequate quantities. Initially, sweat collection
devices consisted of an occlusive bandage formed by one
to three layers of filter paper or pieces of cotton, gauze
or towel (Kintz and Samyn, 2000). Heat or chemicals
(e.g. pilocarpine) were used to increase sweat produc-
tion. However, this kind of patch was time-consuming
to apply, uncomfortably large, prone to detachment
and yielded a small volume of sweat for analysis. In
addition, it was found to alter the steady-state pH of
the skin, the types of bacteria that colonize the skin and
the transport characteristics of the skin, producing skin
irritation after approximately 24 h (Huestis et al., 1999).
To overcome these difficulties, non-occlusive sweat
collection devices have been developed, consisting of
an adhesive layer on a thin transparent film of surgical
dressing to which a rectangular absorbent pad is
attached. Non-volatile substances from the environment
cannot penetrate the transparent film, which is a
semipermeable membrane over the pad that allows
oxygen, water and carbon dioxide to pass through the
patch, leaving the skin underneath healthy (Kintz and
Samyn, 2000). During wearing of the patch, as sweat
saturates the pad and slowly concentrates it, drugs
present in sweat are retained, while water evaporates
from the patch. Using this non-occlusive design it is not
possible to quantitate the concentrations of analytes
in sweat, since the whole volume of secreted sweat is
not known. Nevertheless, the wear period may be
extended (usually a wear period of seven days is used)
without skin irritation. Therefore, a cumulative record
of drug exposure can be obtained (Huestis et al., 1999).
In addition, the sweat patches have a unique identifi-
cation number, which aids with chain of custody and
identification. On the other hand, the patch’s design
makes sample adulteration difficult, because attempts
to remove it before the end of the collection period
or tamper with it are readily visible to personnel
trained to monitor the sweat patch.
Prior to attaching the patch, skin is cleaned with an
alcohol wipe, both to remove external contamination
from drugs in the environment and to improve patch
adherence. Kidwell and Smith (2001) have shown that
inappropriate cleansing of the skin prior to patch place-
ment can result in contamination of the patch. Careful
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preparation of the skin prior to application of a collec-
tion device helps to reduce the possibility of bacterial
growth and previous skin contamination.
Several papers have been published on sweat testing,
including both chromatographic (using mass spectro-
metry) and immunoassay techniques, particularly for
the determination of drugs of abuse. The main detected
drugs are opiates, buprenorphine, amphetamines and
designer drugs, cocaine and metabolites, and GHB. Pres-
cription drugs, such as benzodiazepines and antipsycho-
tics, have also been detected. A summary of the main
detected drugs can be seen on Table 3.
In general, sweat testing has several advantages over
blood and urine, including non-invasive collection,
reduced opportunity for sample adulteration, and in
some cases, longer detection windows than for plasma
or urine. Since the patches are worn for several days,
sweat analysis provides cumulative measure of drug
exposure, detecting both parent drugs and metabolites.
However, as stated above, there is a lack of information
concerning dose–response relationships, and analytes are
present in low concentrations. In addition, care should
be taken during application and removal of the patch,
because of the risk of contamination. Another draw-
back of sweat analysis is related to the impossibility
of knowing accurately the volume of sample that was
collected. In fact, there is considerably inter-individual
variability, due to large variations in sweat production,
which makes it difficult to quantitate the amount of
sweat that is secreted over a period of time. Therefore,
sweat testing is considered a qualitative monitoring
method.
Meconium
Meconium is the first faecal matter passed by a neonate
and it is identified most commonly by its dark green/
black color and a lack of the odor of regular feces. It is
a highly complex matrix consisting of water, mucopoly-
saccharides, bile salts, bile acids, epithelial cells and
other lipids, as well as the residue of swallowed amni-
otic fluid (Gourley et al., 1990; Ostrea et al., 1994;
Kwong and Ryan, 1997; Moore et al., 1998; Chan et al.,
2004; Gareri et al., 2006).
Despite being variably reported to form from within
the first trimester (Browne et al., 1992) to as late as
five months of gestation (Kintz and Samyn, 2000), it is
generally accepted that meconium begins to form at
approximately 12 weeks of gestation, because it is at
this time that fetal swallowing of amniotic fluid begins
(Gareri et al., 2006). The formation of meconium has
been evidenced at this stage by the presence of cocaine
found in the meconium of early gestational fetuses.
Fetal swallowing is thought to be the mechanism by
which drugs are concentrated in the meconium; as the
fetus releases urine into the amniotic fluid, any excreted
compounds and metabolites are then swallowed and
ultimately deposited into the meconium (Browne et al.,
1992; Ostrea et al., 2006). In addition to this mecha-
nism, fetal exposure is a product of maternal consump-
tion, metabolism and elimination, placental transfer and
metabolism, and also fetal metabolism (Chan et al.,
2004).
Some authors state that meconium collection from
a newborn is more successful than urine collection
(Maynard et al., 1991), which makes meconium the
specimen of choice for detecting in utero drug exposure.
Furthermore, drug concentrations in meconium gener-
ally are higher than in urine because of its accumulation
over several months of gestation (Ostrea et al., 2001;
Bar-Oz et al., 2003; Eyler et al., 2005). These factors
make meconium an optimal matrix for identifying
in utero exposure as it is considered a preserved record
of the ultimate exposure by the fetus.
Furthermore, it has been suggested that meconium
is a more sensitive matrix to analyze for neurotoxicants
in the environment when compared with other specimens,
because of its wide window of exposure to these com-
pounds. In fact, there is an ongoing study which com-
pares the analysis of various matrices (maternal blood,
maternal hair, infant hair, cord blood and meconium)
to detect exposure to various pesticides. Preliminary
results among 750 mother/infant dyads shows a signifi-
cantly higher percentage of exposure by meconium
analysis (Ostrea et al., 2006).
One issue that should be taken into account when
analyzing meconium is the possibility of urine contami-
nation, which is likely to occur when a neonate
has been exposed to a drug near-term and evacuates
drug-contained urine into a meconium-soiled diaper,
leading to an increase in the sensitivity of meconium
screening due to the augmentation of drug levels in the
specimen. However, this contamination can interfere
with the development of dose–response relationships
with regard to the level of drugs present in meconium.
Indeed, in this case, the drugs have not been metabo-
lized to the same degree as meconium-deposited drugs,
and therefore the expected relationships between drugs
and metabolites will be different in meconium.
Meconium collection is easy and non-invasive, and
it is achieved by scraping the contents (0.5 g minimum)
of the soiled diaper into a specimen collection container,
for which contributes its thick and viscous nature. Stud-
ies indicate that drugs are stable in this specimen for
up to 2 weeks at room temperature and for at least
1 year if frozen (Kintz and Samyn, 2000).
One major advantage of meconium is a relatively
wide window for sample collection. Indeed, meconium
contents can provide a history of a fetal swallowing and
bile excretion, representing a window of prenatal drug
exposure of about 20 weeks prepartum (Moore et al.,
1998; Kintz and Samyn, 2000). It represents, therefore,
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a repository for many compounds that the fetus has
been exposed to during gestation, including a wide vari-
ety of licit and illicit drugs, food additives and heavy
metals (Bielawski et al., 2005).
After birth, meconium is excreted by the neonate
several times a day for the first 1–5 days postpartum.
Studies using zinc coproporphyrin (a meconium-specific
bile pigment) as a marker have determined that meconium
is fully evacuated by 125 h post-natally (Gourley et al.,
1990). Despite these findings, viable analysis appears to
be optimal via collection within 72 h, since in the later
stages of meconium excretion a matrix of meconium
and feces is produced. For instance, analysis of meconium
for cocaine and opiates has demonstrated positive re-
sults upon third post-natal day sample collection (Ostrea
et al., 1998). In fact, this window of collection covers
99% of term infants, which pass their first formed stool
by 48 h. On the other hand, in extremely low birth weight
infants, which is of particular interest in the drug-
exposed neonatal population, median age of first stool
is 3 days, with 90% of infants passing their first stool
by day 12 (Verna and Dhanireddy, 1993). For these
reasons, the possibility of sample collection beyond 48 h
post-natally is a remarkable advantage of this matrix
(Ostrea, 2001). In general, it can be assumed that, in a
general neonatal population, meconium can be reliably
collected for drug analysis within the first three post-
natal days.
As meconium is a very complex matrix, its analysis
is often complicated by the presence of large amounts of
interferences, resulting in lower sensitivity as compared
with the urine, which is a much cleaner specimen.
Meconium analyses usually require a thorough,
preliminary clean-up procedure, using liquid–liquid or
solid-phase extraction, prior to any analytical assays.
This step is very important, especially in GC-MS assays,
where sensitivity and specificity are greatly influenced
by background noise. Moore et al. (1995) compared
several extraction techniques including methanol, acidi-
fied water, phosphate buffer with methanol, and glacial
acetic acid and diphenylamine in acetone, the latter
yielding the best sensitivity. The choice of extraction
solvents is based on the physical–chemical characteris-
tics of the drug. For example, Moriya et al. (1994) have
used chloroform–isopropanol (3:1) to extract benzoy-
lecgonine, methamphetamine, morphine and phency-
clidine. However, for practical reasons, pure or buffered
methanol has been the most widely used extraction
medium (Kintz and Samyn, 2000).
Taking into account both matrix complexity and the
implications of a positive result, strict criteria for the
identification of substances in meconium are needed,
since many matrix constituents may elute together with
the compounds of interest. Therefore, except for the
cases where the molecular ions are detected in the mass
spectrum, the presence of breakdown ion masses alone
may not be sufficient to identify unambiguously the
compounds, unless specific ratios of target ion to quali-
fiers are also used.
Enzyme multiplied immunoassay test (EMIT) is the
most commonly employed screening assay, but fluorescence
polarization immunoassay (FPIA), radioimmunoassay
(RIA) and enzyme-linked immunosorbent assay (ELISA)
have also been utilized (Moore et al., 1998; Gareri et al.,
2006). All these provide high sensitivity; for example,
cut-off values for cocaine and metabolites are less than
50 ng/mg (Ostrea, 2001; Bar-Oz et al., 2003; Moore et al.,
1995).
Meconium is particularly useful in documenting in utero
drug exposure (Moore et al., 1998; Gareri et al., 2006;
Lozano et al., 2007; Gray and Huestes, 2007), and a
number of papers have been published on the deter-
mination of several substances, such as cocaine and meta-
bolites, opiates, cannabinoids, amphetamines, biomarkers
of ethanol consumption, pesticides, phtalates, benzo-
diazepines, tobacco compounds and pollutants and
metals, see Table 4.
Other
As stated above, sensitive and specific analytical tech-
niques have enabled drug testing in other alternative
and more complex matrices, with special focus on the
early detection of exposure. This is the case for umbili-
cal cord tissue and umbilical cord blood, amniotic fluid
and vernix caseosa, which may be used to document
in utero drug exposure.
Other alternative specimens, despite being scarcely
used routinely in toxicology, do exist, for example
pericardial fluid and skeletal muscle, mainly used in
post-mortem situations (Garriott, 1991; Moriya and
Hashimoto, 1999).
Umbilical cord tissue and umbilical cord blood.
Umbilical cord tissue is a new alternative specimen,
easily and non-invasively collected at birth, and may
reflect a long window of drug detection, similarly to
meconium. However, using the umbilical cord it is
possible to perform the analyses immediately after birth,
in contrast to meconium analysis, which is inevitably
delayed for up to three days. Several substances have
been detected in this specimen, such as amphetamines,
opiates, cannabinoids and cocaine (Montgomery et al.,
2006), suggesting that it is more sensitive for detecting
amphetamines than, for instance, meconium. Nonethe-
less, the interpretation of results is difficult, due to the
few studies available to date (Gray and Huestis, 2007).
The same goes for umbilical cord blood, which has
been used to detect cotinine, antidepressants and co-
caine (Moore et al., 1993; Dempsey et al., 1998; Pichini
et al., 2000; Hostetter et al., 2000; Hendrick et al., 2003).
It is expected, however, that the window of detection in
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cord blood will be quite short, as occurs with maternal
blood specimens, being only useful for determining
acute exposure to drugs of abuse in the period immedi-
ately previous to delivery (Lozano et al., 2007; Gray
and Huestis, 2007).
Amniotic fluid. This sample consists of a filtrate of
maternal blood. Drugs can enter amniotic fluid by dif-
fusion across the placenta and from excretion of fetal
urine in the latter stages of gestation (Szeto, 1993; Gray
and Huestis, 2007). Amniotic fluid acts as a fetal excre-
tion reservoir, accumulating drugs throughout gestation.
The fetus is potentially re-exposed to drugs excreted
in urine due to continuous swallowing of amniotic fluid.
Another possible route of exposure via amniotic fluid
is transdermal diffusion, early in pregnancy when the
skin is poorly developed and late in pregnancy when
the production of vernix caseosa takes place.
The major disadvantage of amniotic fluid is sample
collection. In fact, this sample can only be non-invasively
collected at birth or as excess specimen from another
necessary medical procedure (e.g. amniocentesis). In
general, this sample is not collected for monitoring
in utero drug exposure alone (Gray and Huestis, 2007;
Lozano et al., 2007). Few papers have been published
on drug detection in amniotic fluid (Moore et al., 1992,
1993; Ripple et al., 1992; Jain et al., 1993).
Vernix caseosa. Vernix caseosa is a thick, white lipid
and cell mixture that covers the fetus starting at about
24 weeks of gestational age. This coating prevents
direct contact of the forming fetal skin with amniotic
fluid. This sample can be easily removed from a new-
born’s skin with gauze prior to the first bath (Gray and
Huestis, 2007).
The mechanism of drug deposition into vernix caseosa
is unknown, but it is possible that the drug is deposited
from amniotic fluid. The only paper using this matrix
was published by Moore et al. (1996), in which cocaine
and metabolites were detected using solid-phase extrac-
tion and chromatographic analysis by GC/MS (Moore
et al., 1996).
Furthermore, the amount of vernix caseosa available
for collection is limited, particularly in post-mortem situa-
tions, which makes weighing specimens, and therefore
quantitative measurements, difficult (Gray and Huestis,
2007).
CONCLUSIONS AND PERSPECTIVES
The use of alternative specimens is gaining a tremen-
dous importance in the field of toxicology, which is in
part due to their non-invasive collection procedures.
Analytical equipment is becoming more and more sen-
sitive and specific, which enables both drug detection
and quantitation in very low amounts, and analyses
where concentrations are expected to be low, such as
in hair and oral fluid. In fact, these are the most widely
used unconventional specimens, particularly because of
their potential use in forensic situations. Nevertheless,
documentation of in utero drug exposure has a major
appeal nowadays, where the fetus may be exposed dur-
ing pregnancy to toxic substances, for instance drugs of
abuse or pollutants. In these situations, meconium plays
an important role, since it is a repository for many
compounds to which the fetus has been exposed during
gestation. While the main drawbacks are adequately dealt
with in cases of hair and oral fluid analyses, further
studies are needed with respect to the other matrices,
particularly to aid the interpretation of results.
Concerning the complexity of these alternative matri-
ces, it is generally mandatory that the samples are
thoroughly cleaned up before chromatographic analysis
can be performed, not only to overcome ion suppres-
sion/enhancement issues (which can compromise the
methods’ precision and accuracy), but also to improve
the detection limits. In fact, the latter is a very
important issue when analyzing these unconventional
samples, since in most situations the amount of sample
available is small.
The improvements seen in analytical technology have
led to the enhancement of the methods’ sensitivity and
accuracy, providing better scientific understanding and
improved test results interpretation. This analytical
instrumentation is becoming accessible to most toxico-
logical laboratories worldwide, and therefore it is
expected that further applications of these unconven-
tional matrices will appear in the near future.
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